Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has ...

A team of scientists from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has identified a ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Scientists at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard have re-engineered ...

Research teams have created a versatile set of gene delivery systems that can reach different neural cell types in the human ...

Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell ...

One of the key advantages of CAR T-cell therapy is that it does not cause the side-effects associated with chemotherapy and ...

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...